Publication: Alendronat tedavisinin senil osteoporozlu hastalarda idrar kalsiyum/kreatinin oranı üze- rine etkisinin değerlendirilmesi
Loading...
Files
Date
2011-01-01
Authors
OKUYAN, BETÜL
SANCAR, MESUT
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Amaç: Bu çalışmada, alendronat kullanan senil osteoporozlu kadınlarda alendronat tedavisinin idrar kalsiyum/kreatinin oranları üzerine etkisinin değerlendirilmesi amaçlanmıştır.
Yöntem: Bu amaçla, tedavi öncesi ve 3 aylık tedavi sonrasında hastaların idrar kalsiyum/kreatinin oranları ölçülmüş ve ayrıca serum
kalsiyum, fosfor, alkalen fosfataz (ALP), paratiroid hormon (PTH)
değerlerinin sonuçları değerlendirilmiştir.
Bulgular: 3 aylık tedaviden sonra idrar kalsiyum/kreatinin oranında
ve serum ALP, kalsiyum ve fosfor düzeylerinde istatistiksel olarak
anlamlı bir düşüş ve serum PTH düzeyinde de bu değişikliklere
cevap olarak anlamlı yükselme görülmüştür (p<0.05).
Sonuç: Tedavi başlangıcında osteoporoz hastalarının tedavi etkinliğinin ve uyuncunun değerlendirilmesi için idrar kalsiyum/kreatinin
oranının izlem parametresi olarak kullanılabileceği sonucuna varılmıştır.
Objective: In this study, it is aimed to assess the effects of alendronate treatment on urinary calcium/creatinine ratio in female patients newly diagnosed as senile osteoporosis and prescribed alendronate treatment. Method: According to this aim, urinary calcium/creatinine ratio were measured at baseline and after 3 months alendronate therapy and also the levels of serum calcium , phosphorus, alkaline phosphatase (ALP), parathyroid hormone (PTH) were evaluated. Results: Statistically significant decreases in serum ALP, calcium and phosphorus levels and urinary calcium/creatinine ratio were observed and as a response to these alterations, serum PTH levels were increased significantly after three months therapy (p<0.05). Conclusion: It was found that urinary calcium/creatinine ratio can be used in evaluation of treatment efficacy and adherence of patients with osteoporosis at the beginning of the therapy
Objective: In this study, it is aimed to assess the effects of alendronate treatment on urinary calcium/creatinine ratio in female patients newly diagnosed as senile osteoporosis and prescribed alendronate treatment. Method: According to this aim, urinary calcium/creatinine ratio were measured at baseline and after 3 months alendronate therapy and also the levels of serum calcium , phosphorus, alkaline phosphatase (ALP), parathyroid hormone (PTH) were evaluated. Results: Statistically significant decreases in serum ALP, calcium and phosphorus levels and urinary calcium/creatinine ratio were observed and as a response to these alterations, serum PTH levels were increased significantly after three months therapy (p<0.05). Conclusion: It was found that urinary calcium/creatinine ratio can be used in evaluation of treatment efficacy and adherence of patients with osteoporosis at the beginning of the therapy
Description
Keywords
Tıp, Sağlık Bilimleri, Dahili Tıp Bilimleri, Tıbbi Ekoloji ve Hidroklimatoloji, Medicine, Health Sciences, Internal Medicine Sciences, Medical Ecology and Hydroclimatology, TIP, ARAŞTIRMA VE DENEYSEL, Klinik Tıp, Klinik Tıp (MED), MEDICINE, RESEARCH & EXPERIMENTAL, CLINICAL MEDICINE, Clinical Medicine (MED), İncelemeler ve Referanslar (tıbbi), Araştırma ve Teori, Reviews and References (medical), Research and Theory, Alendronate, osteoporosis, urinary calcium/creatinine ratio, Alendronat, osteoporoz, idrar kalsiyum/kreatinin oranı, Alendronate, osteoporosis, urinary calcium/creatinine ratio
Citation
Yorukoglu E., OKUYAN B., SANCAR M., Izzettin F. V., "Assesment of the effect of alendronate therapy on urine calcium/creatinine ratio in patients with senil osteoporosis", CLINICAL AND EXPERIMENTAL HEALTH SCIENCES, cilt.1, sa.1, ss.42-46, 2011